Schindler of the Geigy Laboratories showed in 1953 that carbamazepine had anticonvulsant properties, but it was not until 1962 that Blom saw its potential in the treatment of paroxysmal trigeminal neuralgia. Chemically it is a tricyclic compound consisting of two benzine rings linked by an azepine with a short side chain from the nitrogen atom (Fig 1) . It differs only slightly from the anti-depressant imipramine ( Fig 2) and amitriptyline, where the azepine ring is replaced by a cycloheptone ring (Fig 3) .
Carbamazepine has revolutionized the treatment of paroxysmal trigeminal neuralgia. Although it may not effect a permanent cure in all cases, it is the only effective medical treatment and thus has widened the circle of those able to treat this condition. Therefore the potential dangers of carbamazepine must be stressed.
The initial trial in cases of paroxysmal trigeminal neuralgia (Blom 1962) proved highly successful. This led to further series being reported by Blom (1963) , Taylor (1963) , Spillane (1964 ), Vanderfield (1964 , Burke & Selby (1965), Campbell et al. (1966) , Dalessio & Abbott (1966) , Rockuliffe & Davies (1966) , Walsh & Smith (1966) and Redpath & Gayford (1968) . Although most authors are primarily concerned with the effectiver.ss of the drug, they do mention the sideeffects encountered. Some of the more serious side-effects are recorded separately, such as 'Present address: Royal West Sussex Hospital, Chichester 'Present address: Department of Oral Surgery. Guy's Hospital, London aplastic anaemia (Donaldson & Graham 1965 , Dyer et al. 1966 ; jaundice (Ramsey 1967); Stevens-Johnson syndrome (Coombes 1965) ; and chronic discoid lupus erythematosus (Simpson 1966) . These side-effects are summarized in Table  1 ; they occurred in 309 out of 510 patients taking carbamazepine.
Discussion
It could be argued that the cases presented do not represent a fair sample of patients taking carbamazepine, in that both series of cases and individual reports are included together. As the individual cases not included in the series amount to only 7, this is insignificant and does not grossly distort the frequency of side-effects. Rare side-effects need to be stressed because of their severity. A number of these have been observed by only one author and many have been recorded only in individual cases.
The majority of the side-effects are seen in the nervous system, occurring in 34-5 % of patients. (Fig 4) which can also be used for recording the patient's response. No patient should be left permanently on carbamazepine and at the first chance the dose should be reduced, so that the minimum effective dose is always used. Patients 
Conlclulsiont
In spite of the fact that side-effects occur in 60 6",, of patients treated with carbamazepine, this drug still has a place in the primary medical treatment of paroxysmal trigeminal neuralgia. Most of the side-effects are mild and transient; nevertheless, there are troublesome and serious side-effects which stop carbamazepine from being a safe drug in the absence of monitoring. There is also an ever-rising percentage of cases which become resistant with recurrent attacks of neuralgia. A place can always be found for new drugs in this field.
